date,title,source
Oct-18-18,Ultragenyx Announces Approval of Mepsevii (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII,GlobeNewswire
Oct-22-18,Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder),GlobeNewswire
Oct-26-18,Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders,GlobeNewswire
Oct-30-18,Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update,GlobeNewswire
Oct-31-18,"Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal",Zacks
Nov-05-18,"Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates",Zacks
Nov-05-18,Ultragenyx: 3Q Earnings Snapshot,Associated Press
Nov-05-18,Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update,GlobeNewswire
Nov-06-18,Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3,Zacks
Nov-06-18,Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT,Thomson Reuters StreetEvents
Nov-06-18,"Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending",Insider Monkey
Nov-09-18,Ultragenyx to Present at Upcoming Investor Conferences,GlobeNewswire
Nov-09-18,"Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Nov-14-18,Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019,GlobeNewswire
Nov-19-18,Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT,Thomson Reuters StreetEvents
Nov-21-18,Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT,Thomson Reuters StreetEvents
Dec-06-18,Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (burosumab injection) for the Treatment of Xlinked Hypophosphatemia (XLH) in Adults and Children,GlobeNewswire
